UNITY Biotechnology to Participate in the UBS 2022 Global Healthcare Conference
UNITY Biotechnology, Inc. (Nasdaq: UBX) announced that its senior management team will provide a corporate update at the UBS 2022 Global Healthcare Conference on May 25, 2022, at 11:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
UNITY Biotechnology, Inc. (Nasdaq: UBX) announced that its senior management team will provide a corporate update at the UBS 2022 Global Healthcare Conference on May 25, 2022, at 11:30 AM ET. The event will be virtual and accessible via the UBS conference portal. An archived replay will be available for 90 days.
UNITY focuses on developing therapeutics to address aging diseases, particularly through the elimination of senescent cells.
Details
News Market Reaction – UBX
The recorded move for UBX in the trading session of this news was +0.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and participate in one-on-one investor meetings at the UBS 2022 Global Healthcare Conference taking place virtually on Wednesday, May 25th, 2022, at 11:30 AM ET.
The presentation will be available through the UBS conference portal and will also be available through the Investors & Media section of UNITY’s website. An archived replay will be available for 90 days following the event.
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
Media Contact:
Canale Communications
Jason Spark
jason.spark@canalecomm.com
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Source: Unity Biotechnology, Inc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.